What Researchers Did
This review explored the history, uses, and benefits of hyperbaric oxygen therapy (HBOT) and evaluated its effectiveness and underlying mechanisms, including epigenetics, as an intervention for neurodegenerative diseases.
What They Found
The review highlighted that neurodegenerative diseases are projected to be the second leading cause of death in developed countries by 2040, surpassing cancer. It found that hyperbaric oxygen therapy (HBOT), a treatment used for over 50 years, shows promising effects in conditions associated with neurodegeneration and functional impairments.
What This Means for Canadian Patients
For Canadian patients, this review suggests that hyperbaric oxygen therapy (HBOT) could emerge as a valuable intervention for neurodegenerative diseases, which are a growing health concern. While more research is needed, HBOT may offer a new avenue for managing symptoms and improving functional outcomes for those affected.
Canadian Relevance
This review does not have a direct Canadian connection as it is a general exploration of hyperbaric oxygen therapy for neurodegenerative diseases.
Study Limitations
As a review, this study synthesizes existing literature and does not present new empirical data or clinical trial results on HBOT's effectiveness.